ASCO 2018 highlights: metastatic breast cancer.

MEMO-MAG EUR MED ONC. 2018, 11(4): 276-279.

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.

Cell Commun Signal. 2017, 15(1):13.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Leukemia. 2017, 31(4):997-1000.

Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo.

Memo. 2017, 10(1):8-12.

Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Cell Commun Signal. 2017, 15(1): 8.

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.

Ann Hematol. 2017.

Amb a 1 isoforms: unequal siblings with distinct immunological features.

Allergy. 2017.

The Human NADPH Oxidase, Nox4, Regulates Cytoskeletal Organization in Two Cancer Cell Lines, HepG2 and SH-SY5Y.

Front Oncol. 2017, 7:111.

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study.

Anticancer Res. 2017, 37(5):2683-2691.

T cell exhaustion: from pathophysiological basics to tumor immunotherapy.

Cell Commun Signal. 2017, 15(1):.